XTAL is proud to be part of the Chemical Biology Consortium (CBC) in the NCI Experimental Therapeutics (NExT) program, which brings together chemical biologists and molecular oncologists from government, industry, and academia to address unmet needs in therapeutic oncology.


Members of the consortium contribute their expertise in high throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and animal models for oncology to advance early stage drug discovery projects to the clinical candidate stage. Through the CBC and interactions among participants, the NCI’s drug discovery and development pipeline is active from target identification to proof-of-concept clinical trials.

The CBC operates as a collaborative network of 7 Dedicated Centers and 15 Specialized Centers. The Dedicated Centers support the advancement of NExT discovery projects through all discovery stages and provide scientific leadership for the Consortium. The Specialized Centers provide uniquely focused technologies that facilitate progression of NExT discovery projects through specific discovery stages.